Ikonisys SA: Terms and Conditions of Availability of Preparatory Documents for the General Meeting of September 25, 2024

Business Wire · Uhr

Regulatory News:

Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces that the preparatory documents for the General Meeting of September 25, 2024 will be made available to the public. The meeting will be held at 2 pm at the offices of the Jeantet law firm, 11, street Galilée - 75116 Paris.

The notice of meeting serving as a convening notice including the agenda as well as the procedures for participating in and voting at the Meeting was published in the Bulletin of Legal Announcements (BALO) on August 21, 2024.

Documents and information relating to the Combined General Meeting, as well as the single voting form, are available on the Company's investor website, in the "Shareholders" section.

Any shareholder may obtain the documents referred to above under the conditions set out in Articles R.225-88 and R.225-89 of the Commercial Code by sending a written request to the Company's registered office at 62, RUE DE CAUMARTIN, 75009 PARIS.

Shareholders may vote:

  • in person on the day of the General Meeting with an admission card;
  • by post ;
  • or by proxy.

About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.ikonisys.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904520890/en/

Ikonisys
Alessandro Mauri
CFO
investors@ikonisys.com

NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

onvista Premium-Artikel

Diese Depotkandidaten gibt es
Mehr als nur SAP: Diese Alternativen zu US-Tech-Giganten bietet Europa24. Apr. · onvista
Mehr als nur SAP: Diese Alternativen zu US-Tech-Giganten bietet Europa
Reservewährung im Sinkflug
Was der schwächere Dollar für dein Depot bedeutet21. Apr. · onvista
Was der schwächere Dollar für dein Depot bedeutet

Das könnte dich auch interessieren

Drei Fragen an Bernecker 25.04.2025
Wird Trump Powell entlassen? - Lohnt die Abspaltung bei Conti? - Sind US-Bonds in der Krise?gestern, 12:00 Uhr · onvista
Wird Trump Powell entlassen? - Lohnt die Abspaltung bei Conti? - Sind US-Bonds in der Krise?
Diese Depotkandidaten gibt es
Mehr als nur SAP: Diese Alternativen zu US-Tech-Giganten bietet Europa24. Apr. · onvista
Mehr als nur SAP: Diese Alternativen zu US-Tech-Giganten bietet Europa
onvista Mahlzeit 25.04.2025
Intels Weg ist noch weit, Alphabet und T-Mobile USgestern, 13:00 Uhr · onvista
Intels Weg ist noch weit, Alphabet und T-Mobile US
Dax Tagesrückblick 25.04.2025
Dax beendet Handelswoche mit weiteren Gewinnengestern, 17:55 Uhr · onvista
Dax beendet Handelswoche mit weiteren Gewinnen
Börse am Morgen 25.04.2025
Dax setzt Erholung weiter fort - MTU gefragtgestern, 10:10 Uhr · onvista
Dax setzt  Erholung weiter fort - MTU gefragt